SCHEMBL59981

SCHEMBL59981

[CH2]C(C)(CC)CCCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3895632 0.92 TSHR (0.37)
SCHEMBL28161491 0.89 TSHR (0.42)
SCHEMBL28066480 0.89 TSHR (0.42)
SCHEMBL28153705 0.89 TSHR (0.42)
SCHEMBL28271723 0.89 TSHR (0.42)
SCHEMBL28154766 0.89 TSHR (0.42)
SCHEMBL28161603 0.89 TSHR (0.42)
SCHEMBL28154743 0.89 TSHR (0.42)
SCHEMBL3886927 0.89 TSHR (0.42)
SCHEMBL28153838 0.89 TSHR (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3037 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1753708-B1 NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME UNIV BRIGHAM YOUNG (US) 2018-02-21 EP claimed
WO-2006065842-A2 5,6,7,8-TETRAHYDROQUINOLINES AND RELATED COMPOUNDS AND USES THEREOF SYNTA PHARMACEUTICALS CORP. (US) 2006-06-22 WO claimed
EP-1663227-A2 DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS Synta Pharmaceuticals Corporation (US) 2006-06-07 EP claimed
US-20050203119-A1 Dihydropyridine compounds for treating or preventing metabolic disorders SYNTA PHARMACEUTICAL CORP. 2005-09-15 US claimed
WO-2005025507-A2 DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS SYNTA PHAMACEUTICALS CORP. (US) 2005-03-24 WO claimed
CN-114845739-B Pharmaceutical conjugate of eribulin derivative, preparation method and application thereof in medicine 上海森辉医药有限公司 2024-07-16 CN disclosed
CN-113939516-B Methods and compositions for targeting protein degradation 珃诺生物医药科技(杭州)有限公司 2024-07-16 CN disclosed
CN-118344365-A Condensed heteroaryl compound, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-07-16 CN disclosed
CN-118344325-A PI3K selective inhibitors 轩竹生物科技股份有限公司 2024-07-16 CN disclosed
CN-118344364-A Amino-substituted fused heteroaryl compounds, preparation method thereof and application thereof in medicine 江苏恒瑞医药股份有限公司 2024-07-16 CN disclosed
CN-113521299-B Pyrazolopyrimidine derivative or conjugate thereof, preparation method and application thereof 江苏恒瑞医药股份有限公司 2024-07-16 CN disclosed
CN-115103850-B 2-Methoxyestradiol derivatives and medical use thereof 韩国巴斯德研究所 2024-07-12 CN disclosed
WO-2003075917-A1 COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS SIGNAL PHARMACEUTICALS, INC. (US) 2003-09-18 WO disclosed
US-20030158164-A1 Novel antiandrogenic agent CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-08-21 US disclosed
EP-1304334-A1 NOVEL ANTIANDROGENIC AGENT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-04-23 EP disclosed
EP-0889057-B1 Process for hydrogenating conjugated diene polymer ASAHI CHEMICAL IND (JP) 2003-01-08 EP disclosed
EP-1219631-A1 ANTIANDROGEN AGENTS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-07-03 EP disclosed
US-5886108-A Process for hydrogenating conjugated diene polymer ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1999-03-23 US disclosed
EP-0889057-A1 Process for hydrogenating conjugated diene polymer ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1999-01-07 EP disclosed
US-3954826-A ANTIBACTERIAL INTERMEDIATES TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1976-05-04 US disclosed